Alphamab Oncology announces IND application for innovative PD-L1/αvβ6 bispecific ADC JSKN022 was officially accepted by...

Mabwell announces IND application acceptance for CDH17-targeting ADC 7MW4911 from both NMPA and FDA

Henlius to initiate a Phase 1 multicenter study in US of its PD-L1 ADC HLX43...

Antengene’s ATG-022 clinical study achieves positive results, CR achieved in elderly gastric cancer patient

Huadong Medicine’s innovative MUC-17 ADC HDM2012 completes dosing of first patient in Phase 1 clinical...

Minghui raises $131M ‘pre-IPO’ round to bankroll JAK inhibitor launch, ADC trials